

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability										
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(1) Sodium</b>					366							366	359	98%								0
— Samples and groups —	[mmol/L]																					
<b>Sample A</b>		133	2,1	1,6	366		CVP	133	0,27	4%	127	139	366	361	99%							0
(2) Indirect ISE		133	2,0	1,5	315	0							315									
(3) Direct ISE		135	2,4	1,8	51	0							51									
<b>Sample B</b>		136	2,1	1,5	366		CVP	136	0,26	4%	130	142	366	364	99%							0
(2) Indirect ISE		136	2,0	1,5	315	0							315									
(3) Direct ISE		137	2,5	1,8	51	0							51									
<b>(2) Potassium</b>					365								365	360	99%							0
— Samples and groups —	[mmol/L]																					
<b>Sample A</b>		5,82	0,13	2,2	365		CVP	5,82	0,017	6%	5,47	6,17	365	362	99%							0
(2) Indirect ISE		5,81	0,13	2,2	316	0							316									
(3) Direct ISE		5,86	0,16	2,7	48	0							48									
Other					1	0							1									
							Ix 1															
<b>Sample B</b>		6,86	0,14	2,0	365		CVP	6,86	0,018	6%	6,44	7,28	365	362	99%							0
(2) Indirect ISE		6,86	0,13	1,9	316	0							316									
(3) Direct ISE		6,88	0,18	2,6	48	0							48									
Other					1	0							1									
							Ix 1															
<b>(3) Chloride</b>					366								366	359	98%							0
— Samples and groups —	[mmol/L]																					
<b>Sample A</b>		114	2,9	2,5	366		CVP	114	0,37	7%	106	122	366	360	98%							0
(3) Indirect ISE		114	2,9	2,5	319	0							319									
(4) Direct ISE		115	2,8	2,5	45	0							45									
Other					2	0							2									
							Ix 1, Ix 2															
<b>Sample B</b>		122	2,8	2,3	366		CVP	122	0,36	7%	113	131	366	363	99%							0
(3) Indirect ISE		122	2,8	2,3	319	0							319									
(4) Direct ISE		121	3,3	2,8	45	0							45									
Other					2	0							2									
							Ix 1, Ix 2															
<b>(4) Calcium</b>					343								343	334	97%							0
— Samples and groups —	[mmol/L]																					
<b>Sample A</b>		2,80	0,06	2,1	343		CVP	2,8	0,079	7%	2,6	3	343	336	98%							0
(2) Phot. with o-cresolftalexon		2,80	0,07	2,8	37	0							37									
(3) Photom. with arsenazo III		2,80	0,06	2,2	190	0							190									
(4) Complex Ca-NM-BAPTA		2,79	0,04	1,7	105	0							105									
(6) ISE		2,75	0,03	1,3	10	0							10									
Other					1	0							1									
							Ix 99															
<b>Sample B</b>		2,98	0,06	2,1	343		CVP	2,98	0,083	7%	2,77	3,19	343	335	98%							0

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(4) Calcium</b>					343							343	334	97%									0
Samples and groups	[mmol/L]																						
<b>Sample B</b>		2,98	0,06	2,1	343	CVP	2,98	0,083	7%	2,77	3,19	343	335	98%									0
(2) Phot. with o-cresolftalexon		2,99	0,08	2,9	37							37											
(3) Photom. with arsenazo III		2,97	0,06	2,1	190							190											
(4) Complex Ca-NM-BAPTA		2,99	0,05	1,9	105							105											
(6) ISE		2,95	0,04	1,4	10							10											
Other					1							1											
						1x 99																	
<b>(5) Inorganic phosphate</b>					329							329	319	97%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,34	0,04	3,2	329	CVP	1,34	0,058	10%	1,2	1,48	329	323	98%									0
(1) UV-molybdate method		1,33	0,04	3,2	320							320											
(3) Molybdate-vanadate method		1,35	0,00	0,55	5							5											
Other					4							4											
						4x 2																	
<b>Sample B</b>		1,73	0,04	2,8	329	CVP	1,73	0,065	10%	1,55	1,91	329	322	98%									0
(1) UV-molybdate method		1,73	0,04	2,8	320							320											
(3) Molybdate-vanadate method		1,74	0,03	1,7	5							5											
Other					4							4											
						4x 2																	
<b>(6) Iron</b>					316							316	316	100%									0
Samples and groups	[µmol/L]																						
<b>Sample A</b>		42,4	1,0	2,4	316	CVP	42,4	0,14	15%	36	48,8	316	316	100%									0
(2) Method with ferrozine/ferene		42,5	1,1	2,5	248							248											
(4) Method with TPTZ		42,1	0,74	1,8	65							65											
Other					3							3											
						2x 1, 1x 99																	
<b>Sample B</b>		32,6	0,86	2,6	316	CVP	32,6	0,12	15%	27,7	37,5	316	316	100%									0
(2) Method with ferrozine/ferene		32,7	0,90	2,8	248							248											
(4) Method with TPTZ		32,3	0,59	1,8	65							65											
Other					3							3											
						2x 1, 1x 99																	
<b>(7) Magnesium</b>					316							316	303	96%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,61	0,04	2,8	316	CVP	1,61	0,062	11%	1,43	1,79	316	309	98%									0
(2) Photometry		1,61	0,04	2,8	270							270											
(4) UV enzyme method		1,59	0,03	2,2	45							45											
Other					1							1											
						1x 99																	
<b>Sample B</b>		1,89	0,05	3,1	316	CVP	1,89	0,081	11%	1,68	2,1	316	306	97%									0
(2) Photometry		1,89	0,06	3,2	270							270											
(4) UV enzyme method		1,90	0,04	2,2	45							45											
Other					1							1											
						1x 99																	
<b>(8) Lithium</b>					45							45	42	93%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,23	0,05	4,7	45	CVP	1,23	0,021	12%	1,08	1,38	45	44	98%									0

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(8) Lithium</b>					45							45	42	93%									0	
Samples and groups	[mmol/L]																							
<b>Sample A</b>		1,23	0,05	4,7	45	CVP	1,23	0,021	12%	1,08	1,38	45	44	98%									0	
(1) Flame emission phot.		1,22	0,04	3,6	9							9												
(3) ISE		1,25	0,05	4,0	17							17												
(4) Photometry		1,21	0,05	4,6	17							17												
Other					2							2												
<b>Sample B</b>		0,768	0,04	6,1	45	CVP	0,768	0,017	12%	0,675	0,861	45	42	93%									0	
(1) Flame emission phot.		0,760	0,03	3,9	9							9												
(3) ISE		0,784	0,03	4,3	17							17												
(4) Photometry		0,752	0,05	7,1	17							17												
Other					2							2												
<b>(9) Total protein</b>					355							0										355	348	98%
Samples and groups	[g/L]																							
<b>Sample A</b>		85,7	2,3	2,7	355							0		CRV	86,11	1,0	9%	78,3	93,9		355	353	99%	
(1) Biuret		85,7	2,3	2,7	355	0																		355
<b>Sample B</b>		69,1	1,8	2,5	355							0		CRV	69,46	0,82	9%	63,2	75,8		355	349	98%	
(1) Biuret		69,1	1,8	2,5	355	0																		355
<b>(10) Albumin</b>					347							347	345	99%										0
Samples and groups	[g/L]																							
<b>Sample A</b>		54,8	1,7	3,1	347	CVP	54,8	0,22	10%	49,3	60,3	347	347	100%										0
(1) BCG		54,8	1,7	3,1	319	0						319												
(2) BCP		54,8	1,5	2,8	28	0						28												
<b>Sample B</b>		45,0	1,5	3,4	347	CVP	45	0,20	10%	40,5	49,5	347	345	99%										0
(1) BCG		45,1	1,5	3,4	319	0						319												
(2) BCP		44,3	1,3	2,8	28	0						28												
<b>(11) Osmolality</b>					136							136	129	95%										0
Samples and groups	[mmol/kg]																							
<b>Sample A</b>		301	7,3	2,4	136	CVP	301	1,5	5%	285	317	136	131	96%										0
(1) Osmometer		301	7,1	2,4	134	0						134												
Other					2	0						2												
<b>Sample B</b>		317	6,4	2,0	136	CVP	317	1,3	5%	301	333	136	130	96%										0
(1) Osmometer		317	6,3	2,0	134	0						134												
Other					2	0						2												
<b>(12) Lactate</b>					164							164	158	96%										0
Samples and groups	[mmol/L]																							
<b>Sample A</b>		2,97	0,12	4,1	164	CVP	2,97	0,023	15%	2,52	3,42	164	160	98%										0
(1) UV enzyme method		2,94	0,12	4,1	76	1						76												
(2) Enzyme electrodes		3,18	0,30	9,4	16	0						16												
(3) Photometric enzyme method		2,96	0,10	3,5	72	0						72												
<b>Sample B</b>		4,89	0,21	4,2	164	CVP	4,89	0,039	15%	4,15	5,63	164	161	98%										0
(1) UV enzyme method		4,86	0,21	4,4	76	0						76												

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(12) Lactate</b>					164							164	158	96%							0		
Samples and groups	[mmol/L]																						
<b>Sample B</b>		4,89	0,21	4,2	164	CVP	4,89	0,039	15%	4,15	5,63	164	161	98%							0		
(2) Enzyme electrodes		5,06	0,44	8,7	16							16											
(3) Photometric enzyme method		4,89	0,16	3,3	72							72											
<b>(13) Bilirubin total</b>					372																372	364	98%
Samples and groups	[µmol/L]																						
<b>Sample A</b>		33,3	2,8	8,5	372							0		CRV	32	0,80	21%	25,2	38,8		372	367	99%
(1) Jendrassik-Gróf		34,2	2,8	8,3	62																	62	
(2) DCA, DPD		32,9	2,8	8,5	283																	283	
(4) Oxidation-reduction methods		35,3	0,69	2,0	25																	25	
Other					2																	2	
<b>Sample B</b>		77,6	5,1	6,6	372							0		2x 99 CRV	73,9	1,7	21%	58,3	89,5		372	365	98%
(1) Jendrassik-Gróf		78,6	4,7	5,9	62																	62	
(2) DCA, DPD		76,8	4,8	6,3	283																	283	
(4) Oxidation-reduction methods		83,5	2,4	2,9	25																	25	
Other					2																	2	
<b>(15) Cholesterol</b>					358							9	6	67%							349	345	99%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		5,15	0,19	3,6	358							9	7	78%							349	348	100%
(1) Enzyme method CHOD-PAP		5,16	0,18	3,5	348									CRV	5,129	0,051	9%	4,66	5,6		348		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade)		4,67	0,30	6,3	9	0	CVPG	4,67	0,37	6,5%	4,36	4,98										9	
Other					1	0																1	
<b>Sample B</b>		3,92	0,14	3,6	358							9	7	78%							349	346	99%
(1) Enzyme method CHOD-PAP		3,93	0,14	3,5	348									CRV	4,027	0,040	9%	3,66	4,39		348		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade)		3,46	0,24	6,9	9	0	CVPG	3,46	0,29	6,5%	3,23	3,69										9	
Other					1	0																1	
<b>(16) Glucose</b>					375																375	362	97%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		5,61	0,16	2,8	375							0		CRV	5,467	0,055	asym.	5,02	6,02		375	367	98%
(1) GOD photometry		5,66	0,20	3,6	103																	103	
(2) GOD electrochemical		5,60	0,14	2,5	6																	6	
(3) Method with hexokinase		5,60	0,14	2,5	266																	266	
<b>Sample B</b>		11,7	0,31	2,6	375							0		CRV	11,32	0,11	asym.	10,4	12,5		375	368	98%
(1) GOD photometry		11,6	0,37	3,2	103																	103	
(2) GOD electrochemical		11,6	0,28	2,4	6																	6	
(3) Method with hexokinase		11,7	0,29	2,5	266																	266	
<b>(17) Uric acid</b>					365																365	364	100%
Samples and groups	[µmol/L]																						
<b>Sample A</b>		618	16	2,5	365							0		CRV	612	6,1	12%	538	686		365	365	100%
(2) Enzyme-photomet. m.		618	16	2,5	365	0																365	
<b>Sample B</b>		366	11	3,0	365							0		CRV	361,2	3,6	12%	317	405		365	364	100%

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>								
<b>(17) Uric acid</b>					365							0			365	364	100%					
Samples and groups	[µmol/L]																					
<b>Sample B</b>		366	11	3,0	365							0	CRV	361,2	3,6	12%	317	405	365	364	100%	
(2) Enzyme-photomet. m.		366	11	3,0	365	0													365			
<b>(18) Urea</b>					373							0							373	370	99%	
Samples and groups	[mmol/L]																					
<b>Sample A</b>		15,1	0,50	3,3	373							0	CRV	15,3	0,15	15%	13	17,6	373	371	99%	
(1) UV enzymatic m.(GMD)		15,1	0,51	3,4	363	0													363			
(5) Electrochemical m.		15,0	0,52	3,5	8	0													8			
Other					2	0													2			
<b>Sample B</b>		19,9	0,66	3,3	373							0	CRV	19,92	0,20	15%	16,9	23	373	370	99%	
(1) UV enzymatic m.(GMD)		19,9	0,66	3,3	363	0													363			
(5) Electrochemical m.		19,9	0,37	1,9	8	0													8			
Other					2	0													2			
													1x 2, 1x 99									
<b>(19) Creatinine</b>					374							0							374	354	95%	
Samples and groups	[µmol/L]																					
<b>Sample A</b>		151	8,1	5,4	374							0	CRV	146,6	1,7	13%	127	166	374	355	95%	
(2) Jaffé without depro. (with corr.)		153	10	6,6	185	0													185			
(3) Enzyme		148	5,0	3,3	174	0													174			
(4) Jaffé without depro. (without corr.)		155	10	6,7	11	0													11			
Other					4	0													4			
<b>Sample B</b>		346	13	3,6	374							0	CRV	343,3	3,4	13%	298	388	374	372	99%	
(2) Jaffé without depro. (with corr.)		343	14	4,1	185	0													185			
(3) Enzyme		348	10	3,0	174	0													174			
(4) Jaffé without depro. (without corr.)		348	12	3,6	11	0													11			
Other					4	0													4			
													4x 1									
<b>(20) Triglycerides</b>					358							0							358	334	93%	
Samples and groups	[mmol/L]																					
<b>Sample A</b>		1,33	0,05	3,8	358							0	CRV	1,318	0,013	15%	1,12	1,52	358	355	99%	
(1) Photometric enzyme (GPO-PAP)		1,33	0,04	3,7	340	0													340			
(2) Enzymatic UV method		1,36	0,08	6,4	18	0													18			
<b>Sample B</b>		1,00	0,07	7,0	358							0	CRV	0,955	0,0100	15%	0,811	1,1	358	335	94%	
(1) Photometric enzyme (GPO-PAP)		1,00	0,07	7,0	340	0													340			
(2) Enzymatic UV method		1,01	0,07	7,7	18	0													18			
<b>(21) ALP</b>					367							0							367	356	97%	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		2,68	0,26	9,7	367							0	CRV	2,731	0,0080	24%	2,07	3,39	367	362	99%	
(3) IFCC method		2,68	0,26	9,6	364	0													364			
Other					3	0													3			
<b>Sample B</b>		6,47	0,82	13	367							0	CRV	6,536	0,018	24%	4,96	8,11	367	356	97%	
														3x 1								

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(21) ALP</b>					367							0									367	356	97%	
Samples and groups	[µkat/L]																							
<b>Sample B</b>		6,47	0,82	13	367							0		CRV	6,536	0,018	24%	4,96	8,11		367	356	97%	
(3) IFCC method		6,46	0,82	13	364	0															364			
Other					3	0																3		
														3x 1										
<b>(22) alpha-amylase</b>					350							9	9	100%							341	332	97%	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		8,38	0,43	5,1	350							9	9	100%							341	334	98%	
(1) IFCC method		8,36	0,41	4,9	341	0								CRV	8,325	0,023	15%	7,07	9,58		341			
(1) IFCC method; (149) Siemens (Dade)		10,1	0,50	4,9	8	0	CVPG	10,1	0,51	9,5%	9,14	11,1												
Other					1	0																		
							1x 0/149																	
<b>Sample B</b>		5,08	0,24	4,8	350							9	9	100%							341	336	99%	
(1) IFCC method		5,06	0,23	4,6	341	0								CRV	5,084	0,030	15%	4,32	5,85		341			
(1) IFCC method; (149) Siemens (Dade)		6,16	0,26	4,2	8	0	CVPG	6,16	0,32	9,5%	5,57	6,75												
Other					1	0																		
							1x 0/149																	
<b>(23) AST</b>					373							0									373	364	98%	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		3,33	0,14	4,3	373							0		CRV	3,287	0,013	15%	2,79	3,79		373	365	98%	
(1) IFCC method		3,33	0,14	4,3	372	0																		
Other					1	0																	1	
														1x 99										
<b>Sample B</b>		2,47	0,10	4,2	373							0		CRV	2,444	0,017	15%	2,07	2,82		373	367	98%	
(1) IFCC method		2,48	0,10	4,2	372	0																		
Other					1	0																	1	
														1x 99										
<b>(24) ALT</b>					373							0									373	352	94%	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		1,26	0,07	6,1	373							0		CRV	1,222	0,013	15%	1,03	1,41		373	353	95%	
(1) IFCC method		1,26	0,07	6,1	372	0																		
Other					1	0																	1	
														1x 99										
<b>Sample B</b>		3,86	0,16	4,2	373							0		CRV	3,847	0,020	15%	3,26	4,43		373	371	99%	
(1) IFCC method		3,86	0,16	4,2	372	0																		
Other					1	0																	1	
														1x 99										
<b>(26) CK</b>					331							0									331	326	98%	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		3,54	0,21	6,0	331							0		CRV	3,469	0,037	20%	2,77	4,17		331	327	99%	
(1) IFCC method		3,54	0,21	6,0	330	0																		
Other					1	0																	1	
														1x 0										
<b>Sample B</b>		8,56	0,50	5,8	331							0		CRV	8,555	0,098	20%	6,84	10,3		331	327	99%	
(1) IFCC method		8,56	0,50	5,8	330	0																		
Other					1	0																	1	
														1x 0										

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(27) gamma-GT</b>					366							0									366	362	99%
Samples and groups	[µkat/L]																						
<b>Sample A</b>		2,11	0,06	3,0	366							0	CRV	2,175	0,080	15%	1,84	2,51		366	362	99%	
(1) IFCC method		2,11	0,06	3,0	366	0															366		
<b>Sample B</b>		3,12	0,09	3,1	366							0	CRV	3,176	0,080	15%	2,69	3,66		366	365	100%	
(1) IFCC method		3,12	0,09	3,1	366	0															366		
<b>(28) LD</b>					268							0									268	264	99%
Samples and groups	[µkat/L]																						
<b>Sample A</b>		7,49	0,22	3,0	268							0	CRV	7,378	0,033	18%	6,05	8,71		268	266	99%	
(3) IFCC method		7,49	0,22	3,0	268	0															268		
<b>Sample B</b>		4,32	0,17	3,9	268							0	CRV	4,343	0,023	18%	3,56	5,13		268	264	99%	
(3) IFCC method		4,32	0,17	3,9	268	1															268		
<b>(29) Lipase</b>					168							150	148	99%									0
Samples and groups	[µkat/L]																						
<b>Sample A</b>		1,71	0,21	13	168							150	148	99%									0
(0) Not specified; (1) Abbott		1,80	0,12	6,9	21	0	CVPG	1,8	0,067	24%	1,36	2,24											21
(0) Not specified; (12) Beckman Coulter		1,51	0,12	7,9	6	0	CVPG	1,51	0,17	24%	1,14	1,88											6
(0) Not specified; (58) Beckman Coulter (Olympus)		1,81	0,06	3,8	43	0	CVPG	1,81	0,026	24%	1,37	2,25											43
(0) Not specified; (60) Roche		1,62	0,17	10	68	0	CVPG	1,62	0,050	24%	1,23	2,01											68
(0) Not specified; (179) Siemens (Bayer)		2,15	0,14	6,5	12	0	CVPG	2,15	0,099	24%	1,63	2,67											12
Other					18	0																	0
<b>Sample B</b>		2,27	0,32	14	168							150	149	99%									0
(0) Not specified; (1) Abbott		2,43	0,16	6,5	21	0	CVPG	2,43	0,084	24%	1,84	3,02											21
(0) Not specified; (12) Beckman Coulter		2,08	0,15	7,1	6	0	CVPG	2,08	0,21	24%	1,58	2,58											6
(0) Not specified; (58) Beckman Coulter (Olympus)		2,42	0,08	3,4	43	0	CVPG	2,42	0,031	24%	1,83	3,01											43
(0) Not specified; (60) Roche		2,11	0,26	12	68	0	CVPG	2,11	0,077	24%	1,6	2,62											68
(0) Not specified; (179) Siemens (Bayer)		2,93	0,21	7,1	12	0	CVPG	2,93	0,15	24%	2,22	3,64											12
Other					18	0																	0
<b>(30) Cholinesterase</b>					121							119	112	94%									0
Samples and groups	[µkat/L]																						
<b>Sample A</b>		172	6,8	3,9	121							119	112	94%									0
(1) ECCLS method 37°C		172	6,6	3,8	119	0	CVP	172	1,5	12%	151	193											119
Other					2	0																	0
<b>Sample B</b>		140	5,1	3,7	121							119	113	95%									0
(1) ECCLS method 37°C		140	5,0	3,6	119	1	CVP	140	1,1	12%	123	157											119
Other					2	0																	0
<b>(31) Albumin (elpho)</b>					97							97	89	92%									0
Samples and groups	[-]																						
<b>Sample A</b>		0,624	0,05	8,9	97							97	90	93%									0

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS4/18 - Basic Clinical Chemistry - Serum

Dead line: 12.10.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(31) Albumin (elpho)</b>					97							97	89	92%									0
Samples and groups	[-]																						
<b>Sample A</b>		0,624	0,05	8,9	97	CVP	0,624	0,014	15%	0,53	0,718	97	90	93%									0
(0) Not specified		0,624	0,05	8,9	97							97											
<b>Sample B</b>		0,636	0,04	7,2	97	CVP	0,636	0,012	15%	0,54	0,732	97	94	97%									0
(0) Not specified		0,636	0,04	7,2	97							97											
<b>(32) gamma-globuline (elpho)</b>					97							97	93	96%									0
Samples and groups	[-]																						
<b>Sample A</b>		0,131	0,02	15	97	CVP	0,131	0,050	30%	0,091	0,171	97	93	96%									0
(0) Not specified		0,131	0,02	15	97							97											
<b>Sample B</b>		0,127	0,01	13	97	CVP	0,127	0,041	30%	0,088	0,166	97	96	99%									0
(0) Not specified		0,127	0,01	13	97							97											
<b>(35) alpha-amylase pancreatic</b>					97							97	96	99%									0
Samples and groups	[µkat/L]																						
<b>Sample A</b>		7,35	0,27	3,7	97	CVP	7,35	0,067	10%	6,61	8,09	97	97	100%									0
(1) With IFCC calibration		7,35	0,27	3,7	97							97											
<b>Sample B</b>		4,34	0,17	4,0	97	CVP	4,34	0,043	10%	3,9	4,78	97	96	99%									0
(1) With IFCC calibration		4,34	0,17	4,0	97							97											
<b>(36) Calcium ionised</b>					60							60	56	93%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,66	0,06	3,6	60	CVP	1,66	0,019	10%	1,49	1,83	60	56	93%									0
(2) Direct ISE		1,67	0,05	3,5	55							55											
Other					5							5											
						1x 0, 4x 1																	
<b>Sample B</b>		1,83	0,07	3,8	60	CVP	1,83	0,022	10%	1,64	2,02	60	56	93%									0
(2) Direct ISE		1,84	0,06	3,6	55							55											
Other					5							5											
						1x 0, 4x 1																	

st\_kn\_np

End of report

Printed: 19.10.2018